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Star-related lipid transfer protein 10
(STARD10): a novel key player in alcoholinduced breast cancer progression
Andrea Floris1,2, Jia Luo3, Jacqueline Frank3, Jennifer Zhou1, Sandro Orrù2, Michela Biancolella4, Sabina Pucci4,5,
Augusto Orlandi4,5, Paolo Campagna6, Antonella Balzano6, Komal Ramani1 and Maria Lauda Tomasi1*

Abstract
Background: Ethanol abuse promotes breast cancer development, metastasis and recurrence stimulating
mammary tumorigenesis by mechanisms that remain unclear. Normally, 35% of breast cancer is Erb-B2 Receptor
Tyrosine Kinase 2 (ERBB2)-positive that predisposes to poor prognosis and relapse, while ethanol drinking leads to
invasion of their ERBB2 positive cells triggering the phosphorylation status of mitogen-activated protein kinase.
StAR-related lipid transfer protein 10 (STARD10) is a lipid transporter of phosphatidylcholine (PC) and
phosphatidylethanolamine (PE); changes on membrane composition of PC and PE occur before the morphological
tumorigenic events. Interestingly, STARD10 has been described to be highly expressed in 35–40% of ERBB2-positive
breast cancers. In this study, we demonstrate that ethanol administration promotes STARD10 and ERBB2 expression
that is significantly associated with increased cell malignancy and aggressiveness.
Material and methods: We investigated the effect of ethanol on STARD10-ERBB2 cross-talk in breast cancer cells,
MMTV-neu transgenic mice and in clinical ERBB2-positive breast cancer specimens with Western Blotting and Realtime PCR. We also examined the effects of their knockdown and overexpression on transient transfected breast
cancer cells using promoter activity, MTT, cell migration, calcium and membrane fluidity assays in vitro.
Results: Ethanol administration induces STARD10 and ERBB2 expression in vitro and in vivo. ERBB2 overexpression
causes an increase in STARD10 expression, while overexpression of ERBB2’s downstream targets, p65, c-MYC, c-FOS
or c-JUN induces STARD10 promoter activity, correlative of enhanced ERBB2 function. Ethanol and STARD10mediated cellular membrane fluidity and intracellular calcium concentration impact ERBB2 signaling pathway as
evaluated by enhanced p65 nuclear translocation and binding to both ERBB2 and STARD10 promoters.
Conclusion: Our finding proved that STARD10 and ERBB2 positively regulate each other’s expression and function.
Taken together, our data demonstrate that ethanol can modulate ERBB2’s function in breast cancer via a novel
interplay with STARD10.
Keywords: Breast cancer, Alcohol abuse, STARD10, ERBB2

* Correspondence: marialauda.tomasi@cshs.org
1
Department of Medicine, Cedars-Sinai Medical Center, DAVIS Research
Building 3096A, 8700 Beverly Blv, Los Angeles, CA 90048, USA
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Floris et al. Journal of Experimental & Clinical Cancer Research

(2019) 38:4

Background
Breast cancer is the most common invasive cancer in females worldwide. It accounts for 16% of all female cancers,
22.9% of invasive cancers in women and 18.2% of all cancer
deaths worldwide [1]. The predictive biomarkers in breast
cancer are the estrogen (ER), progesterone (PR) receptors
and human epidermal growth factor receptor HER2 (erbB2/
neu) [2] whose overexpression is associated with a lower
probability of response to tamoxifen and trastuzumab [3].
Currently, the endogenous and environmental factors that
contribute to breast cancer etiology remain elusive, where
tobacco use, unregulated diet and alcohol consumption are
the three-major human cancer risk factors [4]. Epidemiological evidence and experimental studies support a positive
association between alcohol consumption and breast cancer
risk in a concentration- and duration-dependent manner,
showing that alcohol drinking increases breast cancer risk
by 10–20% for each glass of wine and or beer (10 g of alcohol) consumed daily by adult women [5, 6]. Research consistently shows that ethanol is a tumor promoter and
stimulates migration/invasion as well as proliferation of
breast tumor cells and enhances epithelial-mesenchymal
transition [7], also enhances the cell growth of existing
breast tumor and its capability to invade and metastasize
[8]. Oxidation of ethanol to acetaldehyde or formation of
free radicals could be involved in ethanol-mediated breast
cancer promotion, through inhibition of carcinogen-induced
DNA damage repair [9, 10]. Cytochrome P450 2E1
(CYP2E1) is the principal P-450 responsible for the metabolism of ethanol and it has been shown to contribute to reactive oxygen species (ROS) generation in breast cancer cells
[11]. However, the molecular mechanism underlying ethanol
action remain to be determined. The ErbB protein family is
a receptors kinase group that includes four closely related
members: epidermal growth factor receptor (EGFR/ERBB1),
ERBB2/neu, ERBB3 and ERBB4. ERBB2 plays a critical role
in the pathogenesis of breast cancer and results amplified
and/or overexpressed in 20–30% of human breast cancers
correlating with poor prognosis [12]. In human breast cancer and mammary epithelial cells with high expression of
ERBB2, ethanol induces ERBB2 expression and its autophosphorylation that activates the mitogen-activated protein
kinases (MAPKs) signaling members, extracellular
signal-regulated kinase (ERK), c-Jun NH2 terminal protein
kinase (JNK1/2), p38 mitogen-activated protein kinase (p38
MAPK), PI3-kinase (Phosphatidyl inositol 3 kinase) and Akt
(AK strain transforming), well-known to be downstream targets of ERBB2 [13]. The steroidogenic acute regulatory protein (StAR)-related lipid transfer (STARD) domain is a
protein module of 210 residues that binds lipids [14].
STARD10 is a member of the StarD protein family and lipid
transfer protein with selective binding site to phosphatidylcholine (PC) and phosphatidylethanolamine (PE), two potential precursors for lipid metabolism and a major
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constituent of cell membranes (REF). STARD10 is highly
expressed in liver where it delivers phospholipids in the canalicular membrane for secretion into bile [15]. However, in
the mammary gland, STARD10 expression is developmentally regulated for the lipids needed in milk enrichment [16].
Cellular growth and apoptosis may also be influenced by the
PC to PE ratio as a reduction in this ratio can result in a loss
of membrane integrity that could predispose to cellular
transformation. Since PC is involved in membrane trafficking processes and cellular signaling, it can induce direct activation of the MEK-ERK 1/2 pathway protein, increase cell
viability and induce proliferation [17]. The biological effects
correlated with PC concentration changes in biological
membranes are due to an altered cellular localization of
membrane enzymatic proteins and its activation status [18].
The role of STARD10 as key player in subcellular lipid
transfer and cellular signaling regulation has not been clarified yetPhosphorylation is a common modification that regulates the activity of proteins, increasing their local negative
charge to promote conformational changes or influencing
interaction with protein partners. STARD10 protein is
well-known to be negatively regulated by phosphorylation
via Casein Kinase II (CKII) at Serine 284 [19]. STARD10 is
highly expressed at protein level in mouse mammary tumor,
in 35% of primary breast carcinoma and in 64% of human
breast cancer cell lines. This data supports the role of
STARD10 as lipid binding protein in deregulated cell growth
and tumorigenesis. Intriguingly, STARD10 was found to be
co-expressed with ERBB2 in several breast carcinoma cell
lines, suggesting a selective growth advantage and cellular
transformation for tumor expressing both proteins [16]. Although STARD10 expression alone was not sufficient to
transform cells, it potentiated cellular transformation when
co-expressed with ERBB1, another member of ERBB family,
by an unknown mechanism [16, 19, 20]. The aim of this
study was to investigate the role of STARD10 and ERBB2
cross-talk in breast cancer as consequence of ethanol administration and elucidate the molecular mechanisms.

Materials and methods
Cell culture and treatments

All cell lines were purchased and authenticated after 30
passages from American Type Culture Collection and
authentication service (ATCC, Rockville, MD), respectively. Specifically, both human breast cancer cell lines,
MCF-7 (ERBB2 negative) and SKBR-3 cells (ERBB2 positive), were grown according to instructions provided by
ATCC, while MCF12-A (human breast epithelial cells)
were maintained in DMEM/F12 medium (Corning) containing epidermal growth factor (EGF) (20 ng/mL)
(Thermo Fisher, Waltham, MA), hydrocortisone (0.5
mg/mL), cholera toxin (100 ng/mL), insulin (10 μg/mL)
(Sigma, Saint Louis, MO) and supplemented with 5%
horse serum (Thermo Fisher, Waltham, MA), penicillin
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(100 U/ml)/streptomycin (100 U/ml) at 37 °C with 5%
CO2. In this study, cells were exposed to ethanol (Sigma
Aldrich, St. Louis, MO) at pharmacologically relevant
concentration of 100 mM for 48 h [21].
Human breast tissue specimens

Five normal breast tissues and thirteen breast cancer tissues from surgical reductive mastoplasty and surgical resection for primary breast cancer, respectively, were used
(Additional file 1: Table S1). All tissues were immediately frozen in liquid nitrogen for subsequent RNA and
protein extraction. Written informed consent was obtained from each patient. The study protocol conformed
to the ethical guidelines of the 1975 Declaration of
Helsinki as reflected in a prior approval by Cedars Sinai
Medical Center’s human research review committee.
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indicated into MCF-7 and SKBR-3 cells (0.5 × 106
cells/well, 6-well plates) as described above for 24 h
and ethanol (100 mM) was added as indicated for 48
h. Gaussia luciferase (GLuc) and secreted Alkaline
Phosphatase (SEAP) activities were measured following the manufacturing’s instruction (GeneCopoeia,
Rockville, MD).
ChIP assay

Mice mammary adenocarcinoma tissues was provided
by Dr. Jia Lou (University of Kentucky College of Medicine, Lexington, KT). FVB MMTV-neu transgenic mice
were purchased from Jackson Laboratory (Bar Harbor,
MA). Twelve weeks old mice were divided into two
groups, the (treat group) were fed with ethanol liquid
diet at concentration 6.6% v/v, while the other (control
group) were put on an alcohol-free liquid diet. Both
groups were monitored weekly to observe growth and
development of tumor. The mice with the tumor that increased its size and go beyond 20 mm were euthanized
and the tumor mass was analyzed [22].

ChIP assays were performed using Imprint Chromatin
Immunoprecipitation kit (Sigma, St. Louis, MO). Sonicated chromatin was immunoprecipitated with 2 μg of
antibody against p65 (Proteintech, Rosemont, IL) reverse
cross-linked and PCR amplified for 35 cycles with the following murine STARD10 promoter primer sequences:
part 1. chr11:72791657–72,796,391) Forward: 5’-TCCT
AATATCCAGAGGAGCAC-3′; Reverse: 5′- TCTG
GAAGTTAACTGACAGCC-3′; part 2. (chr11:72791657–
72,792,196) Forward: 5’-GGCTCTCAGTTAACTTCCA
GA-3′; Reverse: 5’-GCACAACTAACTCAGCAGCAA-3′,
and murine ERBB2 promoter primer sequences: part 1.
(chr11:98411386–98,411,757) Forward: 5’-GAAAGTAGA
TTAAGAGAGGGCC-3′; Reverse: 5’-GTTCTGACT
TTACCCAGTTCTC-3′ (Ambion, Austin, TX). Human
STARD10 promoter primer sequences are: Forward 5’-CT
TGAGCTCCTGAGAAATGTAGT-3′; Reverse 5’-GAGG
GTCATTCCTTGTAATCAT-3′, while human ERBB2
promoter primer sequences are: Forward 5’-CACAAGG
TAAACACAACACATCC-3′; Reverse 5’-GTAAAGGGC
CCCGTGGGAA-3′.

Transient cell transfection

RNA interference

MCF-7 and SKBR-3 cells were transfected with the following overexpression vectors: StarD10 (Myc-DDK-tagged), ErbB2-EGFP, pCMV4-p65, CMV6-c-Myc-DDK,
pMIEG3-c-Jun, pLX304-Fos-V5. All plasmids and the
corresponding negative control empty vectors were purchased from Origene (Rockville, MD) and Addgene
(Cambridge, MA). MCF-7 and SKBR-3 cells were cultured in 6-well plates (0.5 × 106 cells/well) and transfected using 5 μl of JetPRIME from Polyplus (New York,
NY) with 2 μg of target plasmid per well. After 4 h, the
transfection medium was changed with regular culture
medium to avoid toxicity and the cells were cultured for
additional 44 h (total 48 h of transfection). Ethanol (100
mM) was administrated every 4 h to compensate its
evaporation rate without replacing the culture media
and mRNA and protein expression analysis were performed as indicated.

To perform the RNAi experiments, five different predesigned small interfering RNAs (siRNAs) targeting human
STARD10 (#1 sense sequence: 5’-GGCCAUGAAGAAGA
UGUACtt-3′, antisense: 3’-GUACAUCUUCUUCAUGG
CCtt-5′), (#2 sense sequence 5’-GGCCAUGAAGAAGA
UGUACtt-3′ and antisense: 3’-GUACAUCUUCUUCA
UGGCCtt-5′), (Ambion, Austin, TX),and human RELA (#1
sense sequence: 5’-GCCCUAUCCUUUACGUCAtt-3′, antisense: 3’-UGACGUAAAGGGAUAGGGCtg-5′), (#2 sense
sequence: 5’-GGAGUACCCUGAGGCUAUAtt-3′, antisense: 3’-UAUAGCCUCAGGGUACUCCat-5′) and negative
control siRNA were purchased from Ambion (Austin, TX),
while two human ERBB2 siRNAs were obtained from Qiagen (Hilden, Germany) (#1 catalog no. SI02223571; #2 catalog no.SI00300195). MCF-7 and SKBR-3 cells were cultured
in 6-well-plate (0.5 × 106 cells/well) and transfected using
RNAiMax (5 μl/well) (Invitrogen, Carlsbad, CA) with
STARD10 siRNA (10 nM), ERBB2 siRNA (10 nM), RELA
siRNA (10 nM) or negative control siRNA for 48 h for
mRNA or protein expression analysis. For combined overexpression and silencing, overexpression was performed in the
last 24 h of STARD10, RELA or ERBB2 silencing.

MMTV-neu transgenic mice model

STARD10 and ERBB2 promoter reporter assays

The STARD10 and ERBB2 promoter-luciferase reporter plasmids (GeneCopoeia, Rockville, MD), p65,
c-Jun, c-Fos and c-Myc were co-transfected as
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Real-time PCR analysis

Cell migration assays

Total RNA was isolated using Quick-RNA Kits (Zymo
Research, Irvine, CA), according to the manufacturer’s
protocol, subjected to reverse transcription (RT) by
M-MLV Reverse transcriptase (Invitrogen, CarlsBad,
CA). Two μl of RT product was subjected to real-time
PCR analysis. TaqMan probes for human STARD10,
ERBB2, RELA, c-Myc, c-Fos and c-Jun and the Universal
PCR Master Mix were purchased from ABI (Foster City,
CA). Hypoxanthine phosphoribosyl-transferase 1 (Hprt1)
was used as housekeeping gene. The delta Ct (ΔCt) obtained was used to find the relative expression of genes
according to the formula: relative expression = 2-ΔΔCt,
where ΔΔCt = ΔCt of respective genes in experimental
groups – ΔCt of the same genes in control group.

Cell migration assay was performed using IBIDI
Culture-Inserts (2-well) (Ibidi, Munich, Germany).
MCF-7 and SKBR-3 were plated at a concentration of
5 × 104 cells per 70 μL culture media, and after 24 h of
incubation, culture inserts were removed. Photographs
of the movement of cells into the scratch area were
taken every 24 h until the scratch area had closed using
EVOS XL Imaging System (Life Technologies, Carlsbad,
CA). Wound healing was then analyzed using ImageJ
software (https://imagej.nih.gov/ij/). Each assay was repeated in triplicate.

Western blots

Proteins from MCF-7, SKBR-3 cells and animal breast
tissues were prepared using RIPA buffer containing protease inhibitor cocktail (Sigma, St. Louis, MO) and resolved on 10% SDS- polyacrylamide gels following
standard protocols (Amersham BioSciences, Piscataway,
NJ). Membrane were blotted with STARD10, ERBB2,
ERK, phospho-ERK, c-MYC, p65, c-JUN, c-FOS (Proteintech, Rosemont, IL), control β-actin and Histone 3
(Sigma, St. Louis, MO) antibodies. Membranes were developed by chemiluminescence ECL detection system
(Amersham BioSciences, Pittsburgh, PA) and blots were
quantified using the Quantity OneTM densitometry program (Bio-Rad laboratories, Hercules, CA).
Immobilized metal affinity

Cells were plated in 75cm2 Flask (Corning, NY) (~ 60–80%
confluency) and treated with ethanol (100 mM) for 48 h.
Thus, cells were detached from the culture plate using
0.25% Trypsin-EDTA (Fisher Scientific, Hampton, NH) and
collected by centrifugation at 1000 RPM × 2 min. The total
proteins were extracted as described above and subjected
to immobilized metal affinity chromatography using the
PhosphoCruz Protein Purification Columns (Santa Cruz
Biotechology, Dallas, TX) according to the manufacturer’s
protocols. The phosphoenriched lysates were subjected to
immunoblotting using STARD10 monoclonal antibody.
Cell proliferation and viability

The MTT assay was performed to determine the number
of viable cells in culture using the Cell Counting Kit-8
(Bimake.com, Houston, TX). MCF-7 and SKBR-3 cells
were plated into 96-well-plates (4x103cells/well). 1/10
volume of MTT labeling reagent was added to each well
and incubated at 37 °C for 4 h until the color turned orange. Plate reader was used to measure absorbance of
formazan product at 570 nm, with a reference wavelength of 750 nm.

Measurement of intracellular calcium

Intracellular calcium levels were determined with a
colorimetric calcium detection kit from Abcam
(Cambridge, MA). Briefly, cells grown on 10 mm
dishes and breast tissues from animal model were
lysate and centrifuged at 15,000 RPM for 15 min at
4 °C. The supernatant was collected and reacted with
chromogenic reagent. The absorbance of formed
chromophore was measured at 575 nm using the
SPECTROstar Omega reader (BMG Labtech, Ortenberg, Germany).
Membrane fluidity assay

The membrane fluidity kit from Marker Gene Technologies (Eugene, OR) was used to measure the relative
membrane fluidity in MCF-7 and SKBR-3 cells according to the manufacturer’s protocol. Approximately 5 ×
105 cells were seeded into 4-well Chamber slides
(Thermo Fisher, Waltham, MA), treated with ethanol
(100 mM for 48 h) and transfected with STARD10 plasmid as described above. The slides were treated with
200 μl of perfusion buffer with 20 μM fluorescent lipid
reagent (pyrene decanoic acid) and 0.08% of pluronic
F127. After 1-h incubation the cells were washed twice
with PBS and we recorded fluorescence emissions between 392 and 450 nm in 2 nm steps after excitation at
360 nm with the FLUOstar Omega (BMG Labtech,
Ortenberg, Germany). With increased membrane fluidity, the lipophilic pyrene probe forms excimers upon
interaction. The ratio of excimer (peak around 450 nm)
to monomer (peak around 394–398 nm) IE/IM was calculated as a quantitative measure of membrane fluidity.
Casein kinase II activity assay

Casein Kinase II activity was measured in MCF-7,
SKBR-3 breast cancer cells (1 × 106 cells/well) and 10 mg
of mice breast tissues lysate using the CycLex CK2 Kinase assay kit (Woburn, MA) according to the manufacturer’s recommended protocol.
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Statistical analysis

Data are expressed as mean ± SEM. Statistical analysis was performed using ANOVA and Fisher’s test.
For mRNA and protein levels, ratios of genes and
proteins to respective housekeeping densitometric
values were compared. Significance was defined by
p < 0.05.

Results
STARD10 expression in normal human breast and cancer
tissues

Because STARD10 expression appears to be deregulated in several types of cancer including breast cancer [16], we examined STARD10 mRNA level in 38
independent breast cancer microarray datasets from
the GEO database (Additional file 2: Table S2).
STARD10 mRNA levels were at least 5- and 10-fold
higher in DCIS and IDC, respectively, then normal
breast tissues (Fig. 1a). Consistent with these results,
all 13 ERBB2-positive breast tumors (Additional file 1:
Table S1) that we tested had 3- and 4-fold higher
levels of STARD10 and ERBB2 mRNA, respectively,
compared to normal breast tissue (Fig. 1b, left panel).
In normal breast tissues, STARD10 expression was
not detectable at protein level, while in ERBB2 positive human breast cancer tissue, it was expressed in
30% of samples (Fig. 1b, right panel). To confirm that
high level of ERBB2 expression correlates with its
downstream targets, we next measured ERK and
p-ERK protein levels in the same human tissue samples that indicated both proteins levels increased
compared to control (Fig. 1b, right panel). This data
supports the literature which states that STARD10 is
overexpressed in 35% of primary human breast cancers and positively correlates with ERBB2 overexpression [16, 20].
STARD10 and ERBB2 expression in human breast cell
lines

All cell lines that overexpressed ERBB2 mRNA were
found to have high STARD10 levels. STARD10 expression, however, was also detected in cell lines that did
not overexpress ERBB2 [16]. Here, we confirmed that
STARD10 was highly expressed independently of ERBB2
level (Fig. 1c). Specifically, both MCF-7 and SKBR-3
cells exhibited a gain of STARD10 protein level even
though its mRNA level appeared to be upregulated only
in MCF-7 cells, compared to normal MCF-12A cells
(Fig. 1c). This finding confirmed the immunohistochemical analysis that show STARD10 expression was negligible in normal breast tissue [16]. Alterations in
hormone homeostasis during breast cancer transformation may be responsible for the induction in STARD10
expression even though no evidence is presented so far.
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Alcohol administration enhances STARD10 protein level
in MMTV-neu transgenic mice and in breast cancer cell
lines

Luo’s laboratory demonstrated that alcohol feeding in
the FVB MMTV Neu transgenic mice, that express high
levels of neu (ERBB2 in human), increased cancer metastasis activating ErbB2/p38γ MAPK signaling pathway
[22]. Here we investigated whether alcohol influences
STARD10 expression in the above animal model. Alcohol administration increased STARD10, ERBB2 and
p-ERK protein levels by 6.8-, 4.8- and 1.5-fold compared
to control tumor tissues (Fig. 2a). Ethanol administration
in ERBB2 negative MCF-7 cell line promoted the expression of ERBB2 itself in these cells converting them to a
ERBB2 positive state that was associated with a 1.6-fold
induction in STARD10 mRNA (Fig. 2b). ERBB2 positive
SKBR-3 cells also responded positively to ethanol treatment by enhancing both STARD10 and ERBB2 mRNA
levels (2.2 and 2.6-fold compared to controls, Fig. 2c).
This correlates well with our in vivo mouse tumor data
where ERBB2 positivity is observed (Fig. 2a). A comparable induction in STARD10 and ERBB2 protein levels
was observed upon ethanol exposure in MCF-7 and
SKBR3 cells (Fig. 2b and c). Activated ERK (p-ERK) regulates growth factor-responsive targets in the cytosol
and it is well-known function downstream of ERBB2
[23]. Hence, we evaluated its activation status in vitro.
p-ERK was found significantly increased by 2-fold after
alcohol treatment compared to control (Fig. 2b and c) as
we previously found in the in vivo model (Fig. 2a).
STARD10-ERBB2 crosstalk upon ethanol treatment in vitro
and in vivo

Since our preliminary data proves that ethanol treatment
causes STARD10 and ERBB2 upregulation in vivo and in
vitro (Fig. 2), we further explored the role of STARD10
in ethanol-induced tumor promotion to test the hypothesis that STARD10 and ERBB2 cooperate in ethanol induced breast cancer. We overexpressed STARD10 for 24
h in vitro which caused 3- and 1.6-fold induction of
ERBB2 mRNA levels in MCF-7 and SKBR-3 cell lines,
respectively, when compared with empty vector control
(Fig. 3a), while forced expression of ERBB2 caused a 2and 1.8-fold increase in STARD10 mRNA level in
MCF-7 cells (Fig. 3a) and SKBR-3 (Additional file 3: Figure S1A), compared to control vector. Similar results
were found at protein levels. Specifically, STARD10 and
ERBB2 overexpression raised the level of ERBB2 protein
by 1.6- and 1.8-fold in MCF-7 cells (Fig. 3a) and SKBR-3
cells (Additional file 3: Figure S1A), respectively,
compared to empty vector control. Intriguingly, we
found that 48 h ERBB2 knockdown lowers the endogenous mRNA level of STARD10. Moreover, ethanol requires ERBB2 to induce STARD10 expression
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Fig. 1 Expression of STARD10 in breast cells and tissues. a STARD10 mRNA level from 28 independent breast cancer microarrays of DCIS and IDC (GEO
database) compared to normal breast tissue. The database normalized STARD10 expression by RMA (robust multi-array average) method. *p < 0.001 vs.
normal breast. b RT-PCR analysis of STARD10 and ERBB2 expression in 10 primary ERBB2-positive human breast tumors compared to normal breast
tissues. Western blotting analysis of STARD10, ERBB2, pERK, and ERK (right panel). Results represent mean ± SE from 15 samples. *p < 0.04 vs. normal
breast. cMCF-12 cells were used as negative control. mRNA levels of STARD10 in MCF-7 and SKBR-3 cells were compared to mRNA expression in MCF12 cells using RT-PCR. Western blotting was performed to measure STARD10 and ERBB2 protein levels. Results are expressed as a fold relative to
control (mean ± SE) from 10 experiments. *p < 0.002 vs. STARD10 MCF-12 cells

in both MCF-7 and SKBR-3 cell lines (Fig. 3b and
Additional file 3: Figure S1B). This finding suggests
that STARD10 and ERBB2 positively regulate each
other’s expression in breast cancer cells.
Ethanol-induced p65 expression promotes STARD10 and
ERBB2 expression in vivo and in vitro

The stress-responsive transcription factor NF-κB is activated by a variety of cytotoxic conditions and it is considered to be the major downstream event of ERBB2
overexpression [24]. In order to investigate whether p65
was involved in ethanol-induced STARD10 and ERBB2
expression, PROMO™ software [25] was used to predict
the transcriptional factors (TFs) that could potentially

bind and regulate both STARD10 and ERBB2 promoters.
We provided evidence that in human STARD10 promoter,
p65, c-MYC, c-FOS and c-JUN are the predominant TFs
that co-occupy this region (chr11:72791657–72,795,657)
(Additional file 4: Figure S2A). All the above overexpressed TFs positively regulated STARD10 expression
(Additional file 4: Figure S2B and S2C) in MCF-7 cell except c-JUN even though several binding sites were found
in STARD10 promoter sequence (Additional file 4: Figure
S2A). One of the more interesting finding was that p65
had the stronger induction at protein level of STARD10
compared to the other TFs (Additional file 4: Figure S2D).
Alcohol consumption is associated with higher expression
of NF-kB p65 that stimulates tumor growth and
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Fig. 2 Ethanol induces STARD10 expression in vivo and in vitro. a Western blotting analysis of STARD10 and ERBB2 expression in ethanol-fed
MMTV-neu transgenic mice. Densitometric ratios normalized to actin are shown in the right panel. Results are expressed as fold relative to control
(mean ± SE) from 4 mice per group. *p < 0.05 vs. control group. b, c MCF-7 and SKBR-3 cells were plated at density of 0.4 × 106 cells in 6-well/
plates and treated with 100 mM ethanol for 48 h. The mRNA levels of STARD10 and ERBB2 in ethanol-treated MCF-7 and SKBR-3 cells were
measured by RT-PCR and compared to control. STARD10, ERBB2, pERK, and ERK were analyzed using Western blotting. Results are expressed as
fold relative to control (mean ± SE) from 5 experiments. *p < 0.02 vs control left panel; *p < 0.01 vs. control rigth panel

aggressiveness [26]. Indeed, p65 overexpression had similar effect as ethanol treatment on STARD10 and ERBB2
promoter activities that were induced by 4- and 3-fold in
both MCF-7 and SKBR-3 cell lines, respectively, compared
to empty vector. This was associated with a corresponding
increase in STARD10 and ERBB2 expression levels (Fig.
3c-d-e and Additional file 3: Figure S1C-D). This finding
was also confirmed analyzing the p65 protein level in the
FVB MMTV Neu transgenic mice, where it was strongly
induced by 2.7-fold in ethanol-fed mouse tumor

compared to control tumor and the p65 nuclear translocation inhibitor, IkappaB-alpha (IkBα) [27] was reduced by
80% compared to control (Fig. 3e).
In order to demonstrate that ethanol positively regulates both STARD10 and ERBB2 expression via p65
involvement, we performed the RELA gene silencing
in vitro to test our hypothesis. Figure 4a and Additional file 5: Figure S3A clearly show that ethanol required p65 to induce STARD10 and ERBB2 promoter
activities in both MCF-7 and SKBR-3 cell lines, in
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Fig. 3 Ethanol-induced p65 positively regulates STARD10 and ERBB2 expression in MCF-7 and MMTV-neu. a mRNA analysis of STARD10 and ERBB2
was accomplished using RT-PCR in MCF-7 cells. 0.4 × 106 cells were transfected and treated with 100 mM ethanol for 48 h. Western blotting
analysis was performed to measure STARD10 and ERBB2 compared to control from 4 indipendent experiments. *p < 0.04 vs. EV. †p < 0.05 vs
STARD10 or ERBB2. b mRNA levels of STARD10 and ERBB2 in MCF-7 cells treated with ethanol (100 mM) and transfected with STARD10
overexpression vector and ERBB2 siRNA (10 nM) for 48 h. Results are expressed as fold relative to Sc + EV (mean ± SE) from 3 independent
experiments. *p < 0.04 vs.Sc + EV; †p < 0.04 vs. STARD10; ‡p < 0.03 vs. EtOH. c STARD10 and ERBB2 promoter activity analysis in MCF-7 cells using
reporter assay from 4 indipendent experiments. *P < 0.04 vs. EV STARD10 promoter. **p < 0.05 vs. EV ERBB2 promoter. d upper panel. RT-PCR
analysis of STARD10 and ERBB2 expression. Cells were treated with 100 mM ethanol or p65 transfection. *p < 0.04 vs. EV. Lower panel. Western
blotting analysis of STARD10, ERBB2, p65. Results are expressed as fold relative to EV (mean ± SE) from 3 independent experiments. *p < 0.05 vs.
EV. e Western blotting analysis of p65 and IkBα in ethanol-treated MMTV-neu mice. Results are expressed as fold relative to control (mean ± SE)
from 4 mice per group. *p < 0.05 vs. control tumor

addition this trend was confirmed by measuring the
mRNA levels of these two genes (Fig. 4b and Additional file 5: Figure S3B). This data also confirmed
previously published findings showing the ability of
p65 to bind and regulate ERBB2 promoter [28].

Ethanol promotes p65 nuclear translocation and its
binding to STARD10 and ERBB2 promoter sequences

Since NF-κB is also an important redox-sensitive TF and
ethanol increased intracellular ROS level [29, 30], we
postulated that ethanol activates NF-κB signaling. NF-κB
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Fig. 4 p65 positively regulates ethanol-induced STARD10 and ERBB2 expression binding their promoter sequences in MCF-7 cells. a
STARD10 and ERBB2 promoter activity assay and RT-PCR for STARD10 and ERBB2 mRNA levels were measured in MCF-7 cells treated with
100 mM ethanol and transfected with sip65 (10 nM) for 48 h.. *p < 0.03 vs. Sc. †p < 0.04 vs. EtOH for STARD10 promoter; *p < 0.04 vs. Sc.
†p < 0.04 vs. EtOH for ERBB2 promoter. *p < 0.004 vs. Sc; †P < 0.03 vs. EtOH for mRNA levels. b mRNA levels of STARD10, ERBB2 and RELA
measure by RT-PCR from 3 indenpendet experiments. *p < 0.004 vs. Sc; †p < 0.03 vs. EtOH. c Western blotting analysis of p65 in nuclear
and cytoplasmic fractions. Nuclear marker (H3) and cytosolic marker (tubulin) were immunoblotted to demonstrate fraction purity. Data
are expressed as (mean ± SE) from triplicate of 4 independent experiments. *p < 0.05 vs. control. d ChIP analysis for p65 binding to
STARD10 and ERBB2 promoters. Input genomic DNA (Input DNA) was used as a positive control, while non-specific antibody IgG was used
as a negative control. Results are summarized as the densitometric changes as fold of control after normalizing to input DNA. *p < 0.03
vs. control. e Western blotting analysis of p65 from nuclear and cytoplasmic fractions from ethanol-fed MMTV-neu transgenic mice tumor.
Results are expressed as fold relative to control tumor (mean ± SE) from 4 mice per group. *p < 0.05 vs. control tumor. f ChIP analysis of
p65 binding to ERBB2 and STARD10 promoters in MMTV-neu ethanol-fed transgenic mice tumor. Results are summarized as the
densitometric changes as fold of control after normalizing to input DNA. *p < 0.04 vs. control

activation is associated with nuclear translocation of the
p65 component of the complex and IκBα phosphorylation and degradation [31]. As show in Fig. 4c and in

Additional file 5: Figure S3C, ethanol induced both nuclear and cytoplasmic p65 NF-κB protein levels by 2.9and 1.5-fold in MCF-7 and by 1.6- and 1.3-fold in
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SKBR-3, respectively, indicating that ethanol stimulated
also total p65 in addition of nuclear translocation of p65
NF-κB. Ethanol also enhanced IκB-α decreased the levels
of IκB-α. This finding was also confirmed in vivo ethanol
treated MMTV-neu mice (Fig. 4e). Furthermore, we
demonstrated that ethanol treatment strongly induces
p65 binding to both STARD10 and ERBB2 promoter
sequences in MCF-7 cells by 2.4- and 2.2-fold, and in
MMTV-neu mice by 2.5- and 1.9-fold, respectively
(Fig. 4d and f ). These results indicated that ethanol
exposure activated NF-κB signaling on both STARD10
and ERBB2 promoters in breast cancer cells in vitro
and in vivo.
Ethanol lowers CKII activity in breast cancer

CKII has been described to be a key negative regulator
of STARD10 modulating is phosphorylation status [19].
In order to explore the role of ethanol on STARD10
phosphorylation/activation, MCF-7 and SKBR-3 cell
lines were exposed to 100 mM of ethanol for 48 h and
then phospho-fraction was separated by column chromatography as described in material and methods. The
results show that ethanol increased the STARD10
unphosphorylated fraction by 5-fold compared to the
control and correspondingly decreased the STARD10
phosphorylated fraction by 90% compared to the control
(Fig. 5a). Even though, we found that ethanol has no effects on CKII expression (Fig. 5b and c), its enzymatic
activity decreased after ethanol administration by 40 and
20% in MCF-7 and SKBR-3, respectively (Fig. 5d). These
results have been confirmed in vivo MMTV-neu transgenic mice tissues (Fig. 5e and f ).
Forced expression of STARD10 and ethanol
administration increase membrane fluidity in MCF-7 and
SKBR-3 cell lines

It is well-know that ethanol can influence cell migration
and invasion in vitro that modulates cellular viability,
proliferation, migration, and invasion in cancer cells [22]
[10]. For this reason, membrane fluidity was assayed on
live MCF-7 and SKBR-3 cell lines treated with 100 mM
ethanol or transiently transfected with STARD10 for 48
h using a fluorescent probe. The use of lipophilic pyrene
probes, that undergo excimer formation upon spatial
interaction, is considered one of the best systems to
study membrane fluidity [32]. Measuring the ratio of
excimer (EM 470 nm) to monomer (EM 372) fluorescence, a quantitative monitoring of the membrane fluidity was attained. The confocal microscopy images
showed that ethanol increased the membrane fluidity by
1.4-fold in both cell lines (Fig. 6a), and STARD10 forced
expression resulted in 1.4- and 1.5-fold increases in fluidity (Fig. 6a lower panel).
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Ethanol and STARD10 mediate calcium transport that
increases cytoplasmic calcium concentration

Previous reports have established the fact that increases
in cell membrane fluidity cause an increase in calcium
ion permeability [33]. For the first time, we confirmed
that ethanol administration increases cytoplasmic calcium concentration by 2.2- and 1.2-fold in MCF-7 and
SKBR-3 cell lines, respectively (Fig. 6b). Also, we provide
evidence that STARD10 overexpression enhanced membrane permeability, leading to increased calcium ion uptake by 2.5- and 1.3-fold in MCF-7 and SKBR-3 cell
lines, respectively (Fig. 6b). These results were confirmed in MMTV-neu transgenic mice, that showed a
1.6-fold increase in calcium concentration in the ethanol
group compared to control group (Fig. 6b right panel).
Mechanism of action of ethanol, ERBB2 and STARD10 in
breast cancer cell growth and migration

Several reports demonstrated that ethanol stimulates both
cell proliferation and migration of breast cancer cells [10].
Also, increased ERBB2 expression seems to be correlated
with the ethanol stimulation [22]. In order to demonstrate
that ethanol promotes cell growth and migration via
induced-expression of STARD10 and ERBB2, MCF-7 and
SKBR3 cell lines were treated for 48 h with 100 mM ethanol. MTT assay was performed to determine the effect of
STARD10, ERBB2 and ethanol on cell proliferation, which
revealed that STARD10 overexpression enhanced the viability of the mammary tumor cells compared to control in
a manner similar to ethanol administration and ERBB2
overexpression (Fig. 7a and Additional file 6: Figure S4B).
We also proved by silencing ERBB2 that it was required for
ethanol to sustain the effect on STARD10-mediated cell
growth (Fig. 7b and Additional file 6: Figure S4B).
Wound-healing assay clearly show that ethanol exposure
promoted cell migration by 20% compared to control in
both MCF-7 and in SKBR-3 cell lines (Fig. 7c and Additional file 6: Figure S4C). Similarly, the ectopic expression
of STARD10 and ERBB2 markedly enhanced the cells’ migration ability compared to the control (Figs. 7c and Additional file 6: Figure S4C). STARD10 and ERBB2
co-overexpression caused an induction of migration level,
without a corresponding change in viability in both cell
lines, compared to single overexpression alone (Fig. 7 and
Additional file 6: Figure S4) suggesting us that ERBB2 promoted this migratory event because of STARD10 overexpression. Since STARD10 overexpression induces growth
and migration (Additional file 6: Figure S4), we investigated
whether silencing STARD10 could have the reverse effect
on these parameters. The efficiency of STARD10 siRNA as
assessed by qRTPCR was higher for siRNA#1 compared to
siRNA#2 (Additional file 7: Figure S5A and S5D). Surprisingly, we found that similar to STARD10 overexpression,
its silencing also induced the growth rate of MCF-7 and
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Fig. 5 Effect of ethanol on CKII expression and/or activity in vitro and in vivo. a phosphorylated and unphopshorylated STARD10 in ethanoltreated MCF-7 cells protein extracts (100 mM for 48 h). STARD10 protein levels were analyzed by Western Blotting . The results are expressed as
fold relative to control from 3 independent experiments and normalized with red pounceau. b, c CKII mRNA and protein levels were measured
by RT-PCR and Western blotting, respectively in MCF-7 and SKBR-3 cell lines. CKII protein was normalized with β-actin expression. Three
independent experiments were performed in triplicates. d The CKII enzymatic activity was evaluated as absorbance at 450 nm of cell lysate in
modified kinase reaction buffer and normalized with standard in MCF-7 ans SKBR-3 cells treated with 100 mM ethanol for 48 h. Data are
expressed as (mean ± SE) from 4 independent experiments performed in triplicates. *p < 0.01 vs. control. e Western blotting analysis of CKII in
ethanol-fed MMTV-neu mice tumors. Densitometric ratios normalized to actin is shown in the right panel. Four mice per group were used. f CKII
enzymatic activity assay in MMTV-neu was normalized with standard from 4 mice per group. *p < 0.005 vs. control tumor

SKBR3 cells compared to control siRNA (Additional file 7:
Figure S5B and S5E). Similar to the overexpression results,
siSTARD10 also induced migration capability of MCF-7
and SKBR-3 cells (Additional file 7: Figure S5C and S5F).
The results suggest that a balanced level of STARD10 is important for regulating the proliferative activity in breast
cancer and its dysregulation in either direction (increase or
decrease) leads to an increase in cell proliferation and migration with consequent increase in neoplastic progression.
The findings and proposed scheme of events are summarized in Fig. 7d. Surprisingly the results indicated that

inhibition of STARD10 significantly increased the growth
rate of both cell lines compared to scramble siRNA (Additional file 7: Figure S5B and S5E). Similar results were observed in migration capability of MCF-7 and SKBR-3 cells
(Additional file 7: Figure S5C and S5F). The results suggest
that the steadiness of STARD10 is important for regulating
the proliferative activity in breast cancer and its dysregulation leads to an increase in cell proliferation and migration
with consequent increase in neoplastic progression. The
findings and proposed scheme of events are summarized in
Fig. 7d.
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Fig. 6 Ethanol and STARD10 overexpression increase membrane fluidity and intracellular calcium concentration in vitro and in vivo. a Cells were
treated with ethanol (100 mM) for 48 h or transfected with StarD10. Membrane fluidity assay in MCF-7 and SKBR-3 cells. Typical epifluorescence
microscopic analysis was performed using an excitation filter (350 nm), a dichroic filter (370 nm) and emission filters for monomer fluorescence
(405 nm interference filter) and excimer fluorescence (470 nm cut-on filter). The normalized fluorescence was calculated as a ratio of excimer to
monomer. b Calcium ion concentrations in cell lysates from ethanol-treated or STARD10 transfected MCF-7 and SKBR-3 cells (100 mM for 48 h).
Calcium ion concentration in breast tumor cell lysates from 4 ethanol-fed MMTV-neu transgenic mice. All data are expressed as (mean ± SE) from
3 independent experiments performed in triplicates. *p < 0.05 vs. EV MCF-7 and SKBR-3; *p < 0.04 vs control tumor MMTV-neu

Discussion
Alcohol abuse has been reported to promote mammary
tumorigenesis enhancing cell growth in vitro and in vivo
[34, 22]. In addition to its carcinogenic effect, alcohol
abuse is associated with progression and aggressiveness
of existing mammary tumors [35]. Mammary tissues and
breast cancer cells normally metabolize alcohol by
CYP2E1, ADH, xanthine oxidoreductase (XOR), and
NOX which produces ROS, causing oxidative stress [11,
36, 37]. Specifically, CYP2E1 is one of the most active
ROS-generating CYP450 isoforms and it is considered
the link between oxidative stress and tumor growth. In

addition, CYP2E1 expression in breast cancer cells plays
a role in the migratory capacity, autophagy, ER stress
and metastasis [11].
Human breast cancer cells or mammary epithelial cells
with a high expression of receptor tyrosine-protein kinase ERBB2 exhibited an enhanced response to ethanol-stimulated cell invasion in vitro [22], therefore ethanol
stimulates ROS production in mammary epithelial cells in
an ERBB2-dependent manner [38]. ERBB2 belongs to the
epidermal growth factor receptor (EGFR) family and plays
an important role in cell proliferation and transformation
through formation of heterodimers with EGFR and HER3
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Fig. 7 Ethanol administration, STARD10 and ERBB2 overexpression promote breast cancer cell malignancy in MCF-7 cells. MCF-7 cells were
treated with 100 mM ethanol and transfected with STARD10 and/or ERBB2 for 48 h (a, b) MTT assay showing Data are expressed as (mean ± SE)
from 3 to 4 independent experiments performed in triplicates. *p < 0.05 vs. EV. c Migration assay. Results are shown as total wound area at 0 h
and 48 h. Data are expressed as (mean ± SE) from 4 independent experiments performed in triplicates. *p < 0.05 vs. EV 48 h. d Pathway schematic
depicting known intracellular signaling mechanisms activated downstream of the ethanol administration proposed to mediate cell proliferation as
well as cell migration through STARD10 and ERBB2 activation

[39]. No known ligand has been identified for ERBB2,
ethanol induces its phosphorylation that activates the
mitogen-activated protein kinase MAPK signaling members, extracellular signal-regulated kinase ERK and other
several important signaling cascades well-known to be
downstream target of ERBB2 that play a key role in the
carcinogenesis and aggressiveness of breast cancer [40].
STARD10 is a specific lipid carrier for PC and PE, is
well-known to be overexpressed in Neu/ErbB2-induced
mammary tumors in transgenic mice, in several human

breast carcinoma cell lines, and in 35% of primary human
breast cancers [16]. It was found to be co-expressed with
ERBB2 in Neu tumors and human breast carcinoma cell
lines and was demonstrated to cooperate with ErbB pathway in cellular transformation [20]. In this paper we tried
to elucidate the mechanism by which ERBB2/STARD10
crosstalk promotes ethanol induced cell growth and migration in breast cancer cells. We also provide evidence
that the common transcription factor p65 is involved in
mediating co-expression of STARD10 and ERBB2. Our
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results indicate a mutual induction of STARD10 and
ERBB2 that positively regulates ethanol-induced malignancy/aggressiveness phenotype. This is supported by the
finding that MCF-7 and SKBR-3 cell lines are more susceptible to cell growth and migration when treated with
ethanol, which induces both STARD10 and ERBB2 and
also overexpressing these key players. In resting cells,
NF-kB is cytoplasmic sequestered as a latent complex
bound to one or more members of the IkB protein
family (IkBa, IkBb, IkBe, IkBg). Ethanol stimuli
through ERBB2 phosphorylation activates the mitogen
activated protein kinase (MAPK) signaling members
than induce phosphorylation via activation of the IkB
kinase complex, IKK) and subsequent proteasomal
degradation of IkB inhibitory proteins, activating NF-kB
for nuclear translocation. In the nucleus the p65/p50 heterodimer binds ERBB2 promoter-specific consensus DNA
elements [28] and for the first time we provide evidence
that p65 also binds to STARD10 promoter positively regulating its transcription. STARD10 transfers PC and PE between membranes, replenishing membranes with lipids
metabolized by phospholipases. Lipids are delivered via
monomeric exchange between the cytosolic membrane
surfaces of different organelles. Monomeric exchange requires desorption of the lipid from the donor membrane,
passage through the aqueous phase, and subsequent insertion into the acceptor membrane [41]. This is the first report demonstrating that the increased STARD10 protein
amount can change the membrane fluidity with a consequent increase in membrane permeability to calcium ions
(Ca2+). It is well known that elevated intracellular Ca2+
triggers numerous signaling pathways including protein
kinases such as the calmodulin-dependent kinases
(CaMKs) and the extra-cellular signal-regulated kinases
(ERKs) [42]. These results support a novel hypothesis that
a key mechanism for ethanol-induced STARD10 to promote ERBB2 is via its function as a lipid transporter.

Conclusions
In summary, the data presented in this study clearly
showed that the ability of STARD10 to influence ERBB2
expression and activity may be involve both dependent
and independent lipid binding function. This is the first
report demonstrating that ethanol can modulate in dynamic manner the ERBB2 role through STARD10 involvement in breast cancer.
Additional files
Additional file 1: Table S1. Characteristics of breast cancer tissues from
ErbB2-positive patients. (DOCX 358 kb)
Additional file 2: Table S2. STARD10 expression in human breast cancer
databases. Biological replicates (Rep.) are parallel measurements of biologically
distinct samples that capture random biological variation. (DOCX 358 kb)
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Additional file 3: Figure S1. Ethanol-induced p65 that increaseS
STARD10 and ERBB2 expression in SKBR-3 cells. (A) SKBR-3 cells were
treated with 100 mM ethanol and transfected with STARD10 and/or
ERBB2 for 48 h. STARD10 and ERBB2 mRNA and protein levels were accomplished using RT-PCR and Western blot analysis, respectively, compared to control from 4 independent experiments. *p < 0.05 vs. EV. (B)
mRNA levels of STARD10 and ERBB2 in SKBR-3 cells treated with ethanol
(100 mM) and transfected with STARD10 overexpression vector and
ERBB2 siRNA (10 nM) for 48 h. Results are expressed as fold relative to Sc
+ EV (mean ± SE) from 3 independent experiments. *p < 0.02 vs.Sc + EV;
†p < 0.01 vs. STARD10; ‡p < 0.05 vs. EtOH. (C) STARD10 and ERBB2 promoter activity analysis was performed using reporter assay from 4 independent experiments. *p < 0.02 vs. EV STARD10 promoter; *p < 0.04 vs. EV
ERBB2 promoter. (D) Cells were treated with 100 mM ethanol or transfected with p65 plasmid for 48 h. STARD10 and ERBB2 expression was analyzed by RT-PCR and Western Blotting analysis to measure their mRNA
and protein levels. Results are expressed as fold relative to EV (mean ± SE)
from 3 independent experiments. *p < 0.05 vs. EV mRNA; *p < 0.03 vs. EV
proteins. (PPTX 69 kb)
Additional file 4: Figure S2. ERBB2 and its downstream targets
overexpression positively regulate STARD10 expression in MCF-7 cells. Cell
were treated with 100 mM ethanol for 48 h. (A) ERBB2 downstream targets binding sites on human STARD10 promoter sequence. (B) STARD10
promoter activity by reporter assay. (C) RT-PCR of StarD10 mRNA level.
Results are expressed as percentage relative to EV for promoter analysis
and as fold relative to EV for mRNA level. Statistically significant in four independent experiments. *p < 0.04 vs EV promoter; *p < 0.05 vs EV mRNA.
(D) Protein levels were examined by Western blotting using an antiSTARD10 antibody. Results were expressed as fold relative to EV. Data are
expressed as (mean ± SE) from triplicate of four independent experiments. *p < 0.05 vs. EV. (PPTX 600 kb)
Additional file 5: Figure S3. p65 positively regulates ethanol-induced
STARD10 and ERBB2 expression binding their promoter sequence in
SKBR-3 cells. Cells were treated with 100 mM ethanol and transfected
with p65 siRNA (10 nM) for 48 h (A) STARD10 promoter activity assay. *p
< 0.003 vs. Sc. †p < 0.003 vs. EtOH. ERBB2 promoter activity assay. *p <
0.04 vs. Sc. †p < 0.04 vs. EtOH. (B) Relative expression of STARD10, ERBB2,
and RELA mRNA and the efficiency p65 silencing were determined by
qRT-PCR; *p < 0.05 vs. Sc. †p < 0.0003 vs. EtOH. (C) Nuclear and cytoplasmid p65 protein level were analyzed by Western blotting. Nuclear marker
(H3) and cytosolic marker (tubulin) were immunoblotted to demonstrate
fraction purity. Data are expressed as (mean ± SE) from triplicate of four
independent experiments. *p < 0.05 vs. control. (PPTX 1155 kb)
Additional file 6: Figure S4. Ethanol administration, STARD10 and ERBB2
overexpression promote cell malignancy in SKBR-3 cells. Cells were treated
with 100 mM ethanol and transfected with STARD10 and ERBB2 plasmids or
ERBB2 siRNA (10 nM)for 48 h (A) (B) MTT assay. Data are expressed as (mean
± SE) from 4 to 5 independent experiments performed in triplicates. *p <
0.04 vs. EV; *p < 0.01 vs. Sc + EV; †p < 0.02 vs. EtOH; ‡p < 0.02 vs. STARD10.
(C) Migration assay. Results are shown as total wound area at 0 h and 48 h.
Data are expressed as (mean ± SE) from 5 independent experiments performed in triplicates. *p < 0.05 vs. EV 48 h. (PPTX 600 kb)
Additional file 7: Figure S5. STARD10 silencing increases cell
malignancy in vitro. MCF-7 and SKBR-3 cells were transfected with two
different STARD10 siRNAs (10 nM) for 48 h. (A)(D) Efficiency of STARD10 silencing was determined by qRT-PCR. Data are expressed as (mean ± SE)
from 3 independent experiments performed in triplicates.*p < 0.001 vs. Sc
MCF-7 cells; *p < 0.001 vs. Sc SKBR-3 cells (B)(E) MTT assay showing viability of MCF-7 cells transfected with two different StarD10 silencers. Data
are expressed as (mean ± SE) from 3 independent experiments performed
in triplicates. *p < 0.04 vs. Sc MCF-7 cells; *p < 0.03 vs. Sc SKBR-3 cells.
(C)(F) Graphs of migration assay. Data are expressed as (mean ± SE) from
4 independent experiments performed in triplicates. 48 h. Results are
shown as percent of wound with compared to Sc at 0 h and 48 h. Data
are expressed as (mean ± SE) from 3 independent experiments performed
in triplicates. *p < 0.04 vs. Sc 0 h MCF-7 cells; †p < 0.05 vs. Sc 48 h MCF-7
cells. *p < 0.05 vs. Sc 0 h; †P < 0.05 vs. Sc 48 h SKBR-3 cells. (PPTX 112 kb)
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